Patents by Inventor Jacques Gilloteaux

Jacques Gilloteaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nontoxic potentiation sensitization of ovarian cancer therapy by supplementary treatment with vitamins
    Publication number: 20070043110
    Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for an ovarian cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
    Type: Application
    Filed: August 14, 2006
    Publication date: February 22, 2007
    Applicant: Summa Health System
    Inventors: Jacques Gilloteaux, Henryk Taper, James Jamison, Jack Summers
  • Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined Vitamins C and K3
    Publication number: 20060229360
    Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 12, 2006
    Inventors: Jacques Gilloteaux, Henryk Taper, James Jamison, Jack Summers
  • Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K
    Patent number: 7091241
    Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: August 15, 2006
    Assignee: Summa Health System
    Inventors: Jacques Gilloteaux, Henryk S. Taper, James M Jamison, Jack L. Summers
  • Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
    Publication number: 20030073738
    Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
    Type: Application
    Filed: June 3, 2002
    Publication date: April 17, 2003
    Inventors: Jacques Gilloteaux, Henryk S. Taper, James M. Jamison, Jack L. Summers